Q-omics provides the consensus-scored NDUFA5 profile across patient tissues and cancer cell-line models. NDUFA5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NDUFA5 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, NDUFA5 protein abundance shows 29,234 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, THCA, and GBM as cancer lineages where NDUFA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA5 survival associations across molecular data types. NDUFA5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA5 RNA expression–survival associations across cancer types. High NDUFA5 expression shows unfavorable associations in SCLC and CHOL, but favorable associations in BRCA, KIRP, KIRC and OV. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for NDUFA5 RNA expression.
This table summarizes NDUFA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA5 shows lower tumor expression in THCA, UCEC, COAD, KIRC and BLCA and higher tumor expression in BRCA. The THCA box plot shows higher NDUFA5 RNA expression in normal versus tumor tissue (log2 FC = −1.303, t-test p < 0.001).
This table shows molecular features associated with NDUFA5 in patient tissues and cancer cell lines. In patient samples, NDUFA5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
